Cadila Healthcare is currently trading at Rs. 448.70, up by 19.25 points or 4.48% from its previous closing of Rs. 429.45 on the BSE.
The scrip opened at Rs. 446.00 and has touched a high and low of Rs. 460.00 and Rs. 438.10 respectively. So far 954666 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 460.00 on 17-Feb-2017 and a 52 week low of Rs. 305.00 on 12-Apr-2016.
Last one week high and low of the scrip stood at Rs. 460.00 and Rs. 356.30 respectively. The current market cap of the company is Rs. 45295.49 crore.
The promoters holding in the company stood at 74.79%, while institutions and non-institutions held 17.18% and 8.03% respectively.
Zydus Cadila has received the final approval from the US Food & Drug Administration (USFDA) to market Fluconazole Tablets USP in strengths of 50 mg, 100 mg, 150 mg and 200 mg and Clobetasol Propionate Spray, 0.05%.
Fluconazole Tablets USP which are used to treat fungal infections will be produced at the group's formulations manufacturing facility at Baddi. Clobetasol Propionate Spray, used in the treatment of various skin disorders will be manufactured at the group's dedicated Topical plant located at Changodar, Ahmedabad.
The group now has more than 105 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.
Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. It is the only Indian pharma company to launch its own patented NCE - Lipaglyn, the world’s first drug to be approved for the treatment of diabetic dyslipidemia.